Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

SmithKline spends dollars 3bn at the chemist

Larry Black
Monday 29 August 1994 23:02 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

SMITHKLINE BEECHAM, the Anglo-American healthcare company, stole a march on its competitors yesterday when it bought Sterling Winthrop, the US non- prescription drugs business, from Kodak for just under dollars 3bn ( pounds 1.9bn).

The deal makes SKB the world's largest supplier of over-the-counter medicines - drugs that can be bought without a doctor's prescription - with combined sales of dollars 2bn last year. That market is the fastest-growing part of the pharmaceutical industry. Among Sterling's products are Panadol, the painkiller and Andrews Liver Salts.

SKB faced fierce competition from powerful contenders such as Procter & Gamble and Germany's Bayer SA. Bayer had hoped to regain North American rights to a best-selling aspirin by that name. Bayer said it would approach SKB about buying the rights.

Yesterday's acquisition is the second big deal by SKB this year. In May it entered the managed- healthcare business in the United States, buying Diversified Pharmaceutical Services for pounds 2.3bn. Earlier this month SKB failed in a bid to buy Cyanamid, the American medical products group, when its offer was trumped by the dollars 9.7bn paid by American Home Products, a pharmaceutical and medical supplies company.

The takeover of Sterling Winthrop is the latest in a series of deals that have seen the fragmented drugs market consolidate. Wall Street was pleased by yesterday's deal, particularly as it comes so soon after the appointment of Jan Leschly as the chief executive of SKB. Shares in both SKB and Kodak rose sharply in New York on the news.

Drugs giants beef up, page 13

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in